1.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 65 and under
Sponsor: Other
Protocol IDs: AML99<=65 años, NCT00390715
|
|
2.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: NCI-D82-018-544, DFCI-80051, DFCI-CML
|
|
3.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 55 and under
Sponsor:
Protocol IDs: FHCRC-458, NCI-V89-0268
|
|
4.
|
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Closed
Age: 35 and under
Sponsor: Other
Protocol IDs: 9504M09637, MT2000-18, NCT00176878
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: under 17
Sponsor:
Protocol IDs: GER-GPOH-AML-BFM-93, EU-93008
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 15 to 60
Sponsor:
Protocol IDs: EORTC-06931, NCT00002549
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: no greater than 65
Sponsor: NCI
Protocol IDs: FHCRC-772.01, NCI-H94-0370
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 16 to 60
Sponsor: NCI
Protocol IDs: SWOG-9328, E-S9328
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: adult
Sponsor:
Protocol IDs: MRC-LU02, EU-94017
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 65 and under
Sponsor: Other
Protocol IDs: PCI-9404, NCI-V94-0494
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP-0060-002, NCI-V95-0712
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 16 to 74
Sponsor:
Protocol IDs: EORTC-06952, ITA-GIMEMA-AIEOP-1, NCT00002701
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: under 15 at initial diagnosis
Sponsor:
Protocol IDs: MRC-LEUK-UKALL-R2, EU-95039
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: over 1 and under 15
Sponsor:
Protocol IDs: MRC-LEUK-UKALL-XI, EU-95036
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: Any age
Sponsor: Other
Protocol IDs: GER-CML-3, EU-95042, NCT00002771
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 2 to 65
Sponsor: Other
Protocol IDs: JHOC-9333, NCI-V96-0897
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 15 to 65
Sponsor: NCI
Protocol IDs: FHCRC-1092.00, NCI-H96-0926, NCT00002789
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: Under 22
Sponsor: NCI
Protocol IDs: COG-2961, CCG-2961, NCT00002798
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 15 to 65
Sponsor: NCI
Protocol IDs: MRC-LEUK-CML-2000, ECOG-E7995, MRC-LEUK-CML-IV, MRC-LEUK-CML-IVa, EU-96029, NCT00002868, E7995
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 21 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: CHP-BMT-583, BMS-CHP-BMT-583, NCI-V97-1183, NCT00002961
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 16 to 60
Sponsor:
Protocol IDs: EORTC-06962, NCT00002989
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: Any age
Sponsor: NCI
Protocol IDs: JHOC-97080106, JHOC-9726, NCI-V98-1453, NCT00003414
|
|
23.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 65
Sponsor: NCI
Protocol IDs: FHCRC-1316.00, PSOC-1604, NCI-G99-1552, NCT00003972
|
|
24.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 16 to 55
Sponsor: NCI
Protocol IDs: SWOG-S9920, NCT00005866, S9920
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 15 to 59
Sponsor: NCI
Protocol IDs: CALGB-19808, NCT00006363
|
